ClinicalTrials.gg
RecruitingNCT07543419ANIMA - ItalyUpdated Nov 16, 2026

Long Term Observational Study to Collect in a Real-world populatIon Data on the Treatment Pattern of Secukinumab in Adult Patients With Moderate to Severe HS Within the Italian Population

An observational study in Hidradenitis Suppurativa, sponsored by Novartis Pharmaceuticals. Recruiting at 22 sites in Italy. Open to participants aged 18 Years to 100 Years. Per ClinicalTrials.gov, last updated 2026-11-16.

Sponsored by Novartis Pharmaceuticals (part of Novartis) · Observational

How we know

From the registry’s dates

  • Started Dec 2025; still recruiting 11 months later.
Updated Nov 16, 20266 sites addedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Other
Enrollment
250
Ages
18 Years to 100 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 21 studies in Hidradenitis Suppurativa by Novartis — 9 open to participants now, 14 under way, 3 of them phase 3. Hidradenitis Suppurativa · Novartis.

Planned enrollment
2nd of 10
250 · median 125
Started
2025
with 6 others
Observational
10 of 21
6 open now
Primary completion
2028-09
later than 11 of 13 live
Registered
14th of 21
by date

Among the 21 studies in Hidradenitis Suppurativa by Novartis, this one is the 2nd largest by planned enrollment of the 10 observational ones that give a count, is one of 7 that started in 2025, is one of 10 observational ones, reaches primary completion later than 11 of the 13 other live ones, and was the 14th registered.

Hidradenitis Suppurativa

286 studies on the registry are indexed under Hidradenitis Suppurativa; 89 are open to participants now.

Browse Hidradenitis Suppurativa studies →

Open to participants now

9 of the 21 studies in Hidradenitis Suppurativa by Novartis are open now, in 12 countries. Recruiting first, the newest first:

3 more — sign in →

By country, each count listing its studies:

All 9 open studies →

Who these studies take

Of the 63 Hidradenitis Suppurativa studies recruiting now, 35 (56%) set no upper age limit and 17 (27%) stop at 75 or younger; 13 take children under 18; 13 take healthy volunteers.

This study: 18 Years to 100 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 21 studies in Hidradenitis Suppurativa by Novartis, or all of them as a file.
02

Study summary

The aim of this study is to generate real-world evidence to fill knowledge gaps regarding the response to secukinumab in patients with moderate to severe HS, its treatment patterns, the clinical characteristics of patients on secukinumab, healthcare resource utilization and the economic impact of HS in Italy.

03

Conditions studied

  • Hidradenitis Suppurativa

Keywords

  • Hidradenitis Suppurativa
  • HS
  • secukinumab
  • NIS
  • LHUs
04

Who can participate

Ages eligible
18 Years to 100 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

The study population will include male and female adult patients (aged ≥ 18 years) with a diagnosis of moderate or severe HS and initiating treatment with secukinumab according to clinical practice

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Study participants eligible for inclusion in this study must meet all the following criteria:

1. Male and Female patients who provide written and privacy form (ICF\&PF) to participate in the study.

2. Aged ≥ 18 years at ICF\&PF signature. 3. Patients with moderate or severe HS (IHS4 and/or Hurley staging system, as assessed by the investigators) at index date.

4. The start of secukinumab is within 30 days after the ICF\&PF signature (enrolment), as per local standard clinical practice. Patients were not treated with secukinumab before enrolment within the Managed Access Program (MAP). The initiation of secukinumab is based on dermatologist's own practice, regardless of study participation.

For HRU and economic burden only:

5. Patients who provide written ICF\&PF to allow the use of secondary (administrative) data for the purposes of this study.

6. Patients with more than 12 months of residence inside the area of competence of the LHU (applicable only to study sites associated with the 6 LHUs).

Exclusion criteria

Exclusion Criteria:

Study participants meeting any of the following criteria are not eligible for inclusion in this study:

7. Participation in an ongoing clinical trial. 8. Any medical or psychological condition that may prevent study participation, based on practitioners' decision-making.

For HRU and economic burden only:

9. Patients will be excluded if the unique identifier does not allow them to be identified in the LHU administrative databases related to the site where they were enrolled.

Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Observational model
Cohort
Time perspective
Other
Enrollment
250 participants (estimated)
Patient registry
No
06

What researchers measure

Primary outcomes

  1. Proportion of patients achieving 55% reduction in IHS4 (IHS4-55) during the observational period.

    Proportion of patients achieving International Hidradenitis Suppurativa Severity Score System 55% reduction(IHS4-55) during the observational period. The IHS4 is an exclusively physician-based, clinical scoring system for dynamic assessment of HS severity. Determining IHS4 requires counting nodules, abscesses and draining tunnels/sinus tracts, which is easy to calculate. The IHS4 score is calculated as the number of nodules (multiplied by 1) plus the number of abscesses (multiplied by 2) plus the number of draining tunnels (multiplied by 4). A score of 3 or less signifies mild HS, a score of 4-10 signifies moderate HS and a score of 11 or higher signifies severe HS

    Time frame: Baseline,6 months and 1 and 1,5 years after initiation of secukinumab

Secondary outcomes

  1. Proportion of patients achieving 55% reduction in IHS4 (IHS4-55) stratified by dosing

    The proportion of patients achieving 55% reduction in IHS4 (IHS4-55) stratified by dosing (q4w / q2w regimen), at 6 months, 1 and 1.5 years after initiation of secukinumab treatment. The IHS4 is an exclusively physician-based, clinical scoring system for dynamic assessment of HS severity. Determining IHS4 requires counting nodules, abscesses and draining tunnels/sinus tracts, which is easy to calculate. The IHS4 score is calculated as the number of nodules (multiplied by 1) plus the number of abscesses (multiplied by 2) plus the number of draining tunnels (multiplied by 4). A score of 3 or less signifies mild HS, a score of 4-10 signifies moderate HS and a score of 11 or higher signifies severe HS

    Time frame: 6 months, 1 and 1.5 years after initiation of secukinumab treatment

  2. Proportion of patients achieving 75% reduction in IHS4 (IHS4-75) and 100% reduction in IHS4 (IHS4-100)

    The IHS4 is an exclusively physician-based, clinical scoring system for dynamic assessment of HS severity. Determining IHS4 requires counting nodules, abscesses and draining tunnels/sinus tracts, which is easy to calculate. The IHS4 score is calculated as the number of nodules (multiplied by 1) plus the number of abscesses (multiplied by 2) plus the number of draining tunnels (multiplied by 4). A score of 3 or less signifies mild HS, a score of 4-10 signifies moderate HS and a score of 11 or higher signifies severe HS

    Time frame: 6 months, 1 and 1.5 years after initiation of secukinumab treatment

  3. Proportion of patients achieving 50% reduction in HiSCR (HiSCR-50) and 75% reduction in HiSCR (HiSCR-75)

    The Hidradenitis Suppurativa Clinical Response (HiSCR) is defined as a ≥ 50% reduction in total AN count (abscesses + inflammatory nodules), and no increase in abscesses or draining tunnels when compared with baseline.

    Time frame: 6 months, 1 and 1.5 years after initiation of secukinumab treatment

  4. Number, type, and localization of HS lesions

    lesion spread is defined as total abscess and inflammatory nodule count (AN) or draining fistulae in a body region not seen at baseline

    Time frame: baseline, 6 months, 1 and 1.5 years after initiation of secukinumab treatment

  5. Change of total abscess and inflammatory nodule count

    Time frame: 6 months, 1 and 1.5 years after initiation of secukinumab treatment

  6. Proportion of patients receiving up-titration

    Proportion of patients receiving up-titration (q4w-to-q2w) of secukinumab

    Time frame: Within 6 months, 1 and 1.5 years after initiation of secukinumab treatment

  7. Proportion of patients receiving down-titration

    Proportion of patients receiving down-titration (q2w-to-q4w) of secukinumab

    Time frame: within 6 months, 1 and 1.5 years after initiation of secukinumab treatment

  8. Time to up-titration and down-titration

    Time to up-titration (q4w-to-q2w) and down-titration (q2w-to-q4w) of secukinumab

    Time frame: Up to 1.5 years

  9. Proportion of patients switching from q4w to q2w treatment

    Proportion of patients switching from q4w to q2w treatment with secukinumab after dose reduction.

    Time frame: 6 months and 1.5 years after initiation of secukinumab treatment

  10. Proportion of patients who receive more than one up- and/or down-titration

    Proportion of patients who receive more than one up- and/or down-titration of secukinumab

    Time frame: within 6 months, 1 and 1.5 years after initiation of secukinumab treatment

  11. Demographics of adult patients with moderate or severe HS

    Descriptive statistics will be performed

    Time frame: Baseline

  12. Proportion of patients achieving a 5-point reduction of Dermatology life quality index (DLQI) score.

    The DLQI is a 10-item general dermatology disability index designed to assess health-related quality of life (HRQoL) in adult subjects with skin diseases. The measure is self-administered and includes domains of daily activities, leisure, personal relationships, symptoms and feelings, treatment, and work/school. The recall period is the last week. Each item has four response categories ranging from 0 (not at all) to 3 (very much). "Not relevant" is also a valid response and is scored as 0. The DLQI total score ranges from 0 to 30, with higher scores indicating greater HRQoL impairment

    Time frame: 6 months, 1 and 1.5 years after initiation of secukinumab treatment

  13. Change in DLQI score from baseline

    The DLQI is a 10-item general dermatology disability index designed to assess health-related quality of life (HRQoL) in adult subjects with skin diseases. The measure is self-administered and includes domains of daily activities, leisure, personal relationships, symptoms and feelings, treatment, and work/school. The recall period is the last week. Each item has four response categories ranging from 0 (not at all) to 3 (very much). "Not relevant" is also a valid response and is scored as 0. The DLQI total score ranges from 0 to 30, with higher scores indicating greater HRQoL impairment

    Time frame: Baseline, 6 months, 1 and 1.5 years after initiation of secukinumab

  14. Clinical characteristics of adult patients with moderate to severe HS

    Clinical characteristics of adult patients with HS moderate or severe

    Time frame: Up to 1.5 years

  15. Proportion of patients with new draining tunnel

    Proportion of patients with new draining tunnel(s) (fistulae/sinuses)

    Time frame: 6 months, 1 and 1.5 years after initiation of secukinumab treatment

  16. Number of areas affected and proportion of patients with additional area involvement

    Time frame: 6 months, 1 and 1.5 years after initiation of secukinumab treatment

  17. Proportion of patients receiving HS-specific concomitant treatments in combination with secukinumab

    Proportion of patient as per clinical practice

    Time frame: Up to 1.5 years

  18. Time of initiation of concomitant medications

    Time of initiation of concomitant medications (after the initiation of secukinumab)

    Time frame: Baseline, 6 months, 1 and 1.5 years after initiation of secukinumab treatment

  19. Duration of treatment with concomitant medications

    Duration of treatment with concomitant medications in a flexible dosing regimen of secukinumab

    Time frame: Up to 1.5 years

  20. Proportion of patients undergoing tapering of concomitant medications

    Proportion of patients undergoing tapering of concomitant medications in a flexible dosing regimen of secukinumab.

    Time frame: Baseline, 6 months, 1 and 1.5 years after initiation of secukinumab treatment

  21. Number and type of surgical interventions

    number and type of surgical interventions (minor and major surgical excision; inpatient, outpatient, or self-treatment at home) in a flexible dosing regimen of secukinumab (q4w and q2w)

    Time frame: 6 months, 1 and 1.5 years after initiation of secukinumab

  22. Reason for surgical intervention

    Time frame: Up to 1.5 years after initiation of secukinumab

  23. Duration of discontinuation/pause of secukinumab treatment before surgery

    Time frame: Up to 1.5 years after initiation of secukinumab

  24. Duration of discontinuation/pause of secukinumab treatment after surgery

    Time frame: Up to 1.5 years after initiation of secukinumab

  25. Reduction in the number of surgical procedures

    Time frame: Up to 1.5 years after initiation of secukinumab

  26. Identification of potential predictors using multivariable analysis

    Time frame: Up to 1.5 years after initiation of secukinumab treatment

  27. Descriptive statistics of pain

    Descriptive statistics of pain (Numerical Skin Pain Rating Scale).

    Time frame: 6 months, 1 and 1.5 years after initiation of secukinumab treatment

  28. Proportion of patients achieving a 30% reduction of Pain Numerical Rating scale (NRS30)

    The Numerical Skin Pain Rating Scale (NRS) is a scale in which the respondent selects a whole number (0-10 integers) that best reflects the intensity of his/her worst skin pain ranging from 0 (no skin pain) to 10 (skin pain as bad as you can imagine).To assess this, the patient should concentrate on the worst pain that his/her skin lesions has generated during the previous 24 hours. NRS30 is a specific threshold used in the assessment of pain reduction in patients with HS. It is defined as a ≥30% and ≥2-point reduction in skin pain on the NRS.

    Time frame: 6 months, 1 and 1.5 years after initiation of secukinumab treatment

  29. Number of patients with secukinumab AEs in routine clinical practice

    Number of patients with secukinumab adverse events (AEs) in routine clinical practice

    Time frame: Up to 1.5 years after initiation of secukinumab treatment

  30. Hospital Anxiety and Depression Scale [HADS] score

    The HADS is a widely used screening tool that helps to identify possible or probable instances of anxiety and depression among patients in non-psychiatric hospital settings. It consists of 14 items, with 7 items related to anxiety (HADS-A) and 7 related to depression (HADS-D), collecting how the patient was feeling in the previous week. Each item is scored from 0 to 3, leading to a maximum score of 21 for each subscale. The HADS is beneficial because it excludes somatic symptoms, which might be caused by physical health problems rather than psychological conditions. It is a quick, reliable, and valid measure that can be self-administered, making it a practical tool for clinicians.

    Time frame: 6 months, 1 and 1.5 years after secukinumab initiation

  31. Healthcare Resource Utilization of adult patients with HS

    describe Healthcare Resource Utilization of adult patients with HS 12 months before and 12 months after secukinumab treatment initiation with administrative claims data

    Time frame: 2 months before and 12 months after secukinumab treatment initiation

  32. Costs of HS covered by the Italian National Health System

    Costs of HS covered by the Italian National Health System (Servizio Sanitario Nazionale, SSN) with administrative Claims data

    Time frame: 12 months before and 12 months after secukinumab treatment initiation

  33. Direct costs not covered by the SSN and indirect costs of HS

    Direct costs not covered by the SSN and indirect costs of HS evaluated through a structured interview between physicians and patients.

    Time frame: 12 months before and 12 months after secukinumab treatment initiation

  34. Analysis on HS-related surgeries per patient and related direct costs covered by SSN

    HS-related surgeries and estimate direct costs of HS-related surgeries covered by the SSN during the period from the date of first HS diagnosis to 12 months after secukinumab treatment initiation with administrative Claims data

    Time frame: 12 months after secukinumab treatment initiation

07

Study locations

22 of 22 sites recruiting
  • Novartis Investigative Site
    Ancona, AN 60020, Italy
    Recruiting
  • Novartis Investigative Site
    Bari, BA 70124, Italy
    Recruiting
  • Novartis Investigative Site
    Brescia, BS 25123, Italy
    Recruiting
  • Novartis Investigative Site
    Cona, FE 44124, Italy
    Recruiting
  • Novartis Investigative Site
    Florence, FI 50122, Italy
    Recruiting
  • Novartis Investigative Site
    Genova, GE 16132, Italy
    Recruiting
  • Novartis Investigative Site
    Lecce, LE 73100, Italy
    Recruiting
  • Novartis Investigative Site
    Messina, ME 98125, Italy
    Recruiting
  • Novartis Investigative Site
    Milan, MI 20122, Italy
    Recruiting
  • Novartis Investigative Site
    Rozzano, MI 20089, Italy
    Recruiting
  • Novartis Investigative Site
    San Donato Milanese, MI 20097, Italy
    Recruiting
  • Novartis Investigative Site
    Modena, MO 41124, Italy
    Recruiting
  • Novartis Investigative Site
    Palermo, PA 90127, Italy
    Recruiting
  • Novartis Investigative Site
    Padova, PD 35128, Italy
    Recruiting
  • Novartis Investigative Site
    Perugia, PG 06129, Italy
    Recruiting
  • Novartis Investigative Site
    Pisa, PI 56126, Italy
    Recruiting
  • Novartis Investigative Site
    Roma, RM 00167, Italy
    Recruiting
  • Novartis Investigative Site
    Roma, RM 00168, Italy
    Recruiting
  • Novartis Investigative Site
    Trento, TN 38100, Italy
    Recruiting
  • Novartis Investigative Site
    Torino, TO 10126, Italy
    Recruiting
  • Novartis Investigative Site
    Udine, UD 33100, Italy
    Recruiting
  • Novartis Investigative Site
    Naples, 80131, Italy
    Recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Dec 2025 (actual). Primary completion is estimated for Sep 2028, 33 months after the start.

Of 46 observational studies under Hidradenitis Suppurativa, half reached primary completion within 34 months of starting (the median), counting those still running; a quarter within 25. This study's planned 33 months is close to that.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 14, 2025
First posted
Apr 21, 2026
StartActual
Dec 17, 2025
Primary completionEst.
Sep 30, 2028
CompletionEst.
Sep 30, 2028
Last update
Nov 16, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
6 sites added
Show 6 added (6 Italy)
  • Novartis Investigative Site · Modena, Italy
  • Novartis Investigative Site · Padova, Italy
  • Novartis Investigative Site · Pisa, Italy
  • Novartis Investigative Site · Roma, Italy
  • Novartis Investigative Site · Roma, Italy
  • Novartis Investigative Site · Torino, Italy
Nov 16, 2026
Show all 1 update
  1. Nov 16, 2026
    6 sites added
    Show 6 added (6 Italy)
    • Novartis Investigative Site · Modena, Italy
    • Novartis Investigative Site · Padova, Italy
    • Novartis Investigative Site · Pisa, Italy
    • Novartis Investigative Site · Roma, Italy
    • Novartis Investigative Site · Roma, Italy
    • Novartis Investigative Site · Torino, Italy
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07543419
Responsible party
Sponsor
First posted
Apr 21, 2026
Start date
Dec 17, 2025
Primary completion
Sep 30, 2028 (estimated)
Completion
Sep 30, 2028 (estimated)
Last update
Nov 16, 2026

Study contacts

Novartis Pharmaceuticals
Contact
novartis.email@novartis.com
+41613241111
Novartis Pharmaceuticals
Contact
Novartis Pharmaceuticals
study director · Novartis Pharmaceuticals
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion